Key facts
- This page summarizes Thomas Garner's Form 3 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 10 Dec 2024, 18:31.
Thomas Garner - 09 Dec 2024 Form 3 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- EVP, Chief Commercial Officer
- Issuer ticker
- ACAD
- Reported as of
- 09 Dec 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 10 Dec 2024, 18:31:19 UTC
- Prior SEC filing
- 12 Feb 2024
- Next SEC filing
- 10 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer J. Rhodes, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas Garner filed Form 3 for ACADIA PHARMACEUTICALS INC (ACAD) on 10 Dec 2024.
Change
- Previous filing in this sequence was filed on 12 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.